Pear Therapeutics Inc (NASDAQ:PEAR) is trading higher Monday following positive analyst coverage from BTIG.
BTIG analyst Marie Thibault initiated coverage on Pear Therapeutics with a Buy rating and announced a $12 price target.
Thibault thinks Pear Therapeutics is one of the best-positioned companies in the prescription digital therapeutics space.
The BTIG analyst highlighted the company's PearCreate and PearConnect platforms, saying that the digital platforms give the company a head start from a regulatory, commercial and operational perspective.
See Also: Why Genprex Shares Are Soaring Today
Pear Therapeutics is engaged in developing and commercializing software-based medicines, called prescription digital therapeutics.
PEAR Price Action: Pear Therapeutics has traded as low as $4.85 and as high as $7.52 over a 52-week period.
The stock was up 25.3% at $7.77 at time of publication.
